Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMED Globus Medical	$59.00 +0.7%	$69.35	$54.48 ▼ $94.93	$8.11B	1.32	1.11 million shs	1.40 million shs
MASI Masimo	$150.13 +0.1%	$158.42	$101.61 ▼ $194.88	$8.14B	1.23	651,386 shs	311,070 shs
TFX Teleflex	$120.95 +0.0%	$131.43	$119.08 ▼ $249.91	$5.34B	1.17	634,351 shs	504,858 shs
THOR Synthorx	$67.99	$67.99	$11.05 ▼ $71.90	$2.20B	N/A	474,507 shs	N/A

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMED Globus Medical	+0.56%	-3.74%	-17.94%	-26.65%	-12.14%
MASI Masimo	+0.15%	-3.53%	-4.94%	-11.67%	+18.59%
TFX Teleflex	-0.03%	-6.35%	-9.13%	-31.06%	-43.24%
THOR Synthorx	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMED Globus Medical	4.6502 of 5 stars	3.4	4.0	0.0	4.1	3.3	2.5	1.9
MASI Masimo	4.8417 of 5 stars	4.4	3.0	0.0	4.2	3.6	3.3	1.3
TFX Teleflex	4.9375 of 5 stars	4.0	5.0	2.5	3.9	2.0	1.7	2.5
THOR Synthorx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMED Globus Medical	2.75	Moderate Buy	$94.00	59.33% Upside
MASI Masimo	2.83	Moderate Buy	$191.60	27.62% Upside
TFX Teleflex	2.09	Hold	$164.63	36.11% Upside
THOR Synthorx	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest THOR, GMED, MASI, and TFX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/12/2025	GMED Globus Medical	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$80.00 ➝ $68.00
5/9/2025	GMED Globus Medical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$100.00 ➝ $80.00
5/7/2025	MASI Masimo	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$193.00
5/7/2025	MASI Masimo	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$215.00 ➝ $200.00
5/7/2025	MASI Masimo	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$204.00 ➝ $185.00
5/7/2025	MASI Masimo	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$205.00 ➝ $190.00
5/5/2025	TFX Teleflex	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$140.00 ➝ $137.00
5/5/2025	TFX Teleflex	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$191.00 ➝ $173.00
5/2/2025	TFX Teleflex	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$150.00 ➝ $145.00
5/2/2025	TFX Teleflex	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$146.00 ➝ $137.00
4/16/2025	TFX Teleflex	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$155.00

(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMED Globus Medical	$2.51B	3.23	$2.53 per share	23.32	$29.32 per share	2.01
MASI Masimo	$2.13B	3.83	$4.88 per share	30.74	$25.79 per share	5.82
TFX Teleflex	$3.01B	1.78	$13.01 per share	9.30	$94.49 per share	1.28
THOR Synthorx	N/A	N/A	N/A	N/A	$6.72 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMED Globus Medical	$122.87M	$1.34	78.66	14.64	1.61	4.09%	10.83%	8.63%	8/5/2025 (Estimated)
MASI Masimo	$81.50M	-$9.17	103.54	32.43	N/A	3.85%	14.98%	6.95%	8/5/2025 (Estimated)
TFX Teleflex	$356.33M	$3.17	24.05	7.97	1.73	7.85%	14.19%	8.53%	8/7/2025 (Estimated)
THOR Synthorx	-$56.61M	-$6.59	N/A	N/A	N/A	N/A	-26.09%	-24.62%	N/A

Latest THOR, GMED, MASI, and TFX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	GMED Globus Medical	$0.74	$0.68	-$0.06	$0.54	$629.74 million	$598.12 million
5/6/2025	Q1 2025	MASI Masimo	$1.24	$1.36	+$0.12	-$3.12	$367.79 million	$372.00 million
5/1/2025	Q1 2025	TFX Teleflex	$2.88	$2.91	+$0.03	$2.07	$699.37 million	$700.67 million
2/27/2025	Q4 2024	TFX Teleflex	$3.86	$3.89	+$0.03	-$2.95	$813.24 million	$795.40 million
2/25/2025	Q4 2024	MASI Masimo	$1.42	$1.80	+$0.38	-$6.52	$593.35 million	$600.70 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMED Globus Medical	N/A	N/A	N/A	N/A	N/A
MASI Masimo	N/A	N/A	N/A	N/A	N/A
TFX Teleflex	$1.36	1.12%	N/A	42.90%	N/A
THOR Synthorx	N/A	N/A	N/A	N/A	N/A

Latest THOR, GMED, MASI, and TFX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/12/2025	TFX Teleflex	quarterly	$0.34	1.09%	5/20/2025	5/20/2025	6/16/2025
2/27/2025	TFX Teleflex	quarterly	$0.34	0.77%	3/7/2025	3/7/2025	3/17/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMED Globus Medical	N/A	2.51	1.64
MASI Masimo	0.50	2.01	1.11
TFX Teleflex	0.37	2.42	1.39
THOR Synthorx	N/A	18.87	18.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMED Globus Medical	95.16%
MASI Masimo	85.96%
TFX Teleflex	95.62%
THOR Synthorx	66.12%

Insider Ownership

Company	Insider Ownership
GMED Globus Medical	18.51%
MASI Masimo	16.90%
TFX Teleflex	1.40%
THOR Synthorx	53.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMED Globus Medical	2,600	137.54 million	110.92 million	Optionable
MASI Masimo	6,200	54.22 million	48.35 million	Optionable
TFX Teleflex	15,500	44.19 million	45.78 million	Optionable
THOR Synthorx	48	32.34 million	N/A	Not Optionable

THOR, GMED, MASI, and TFX Headlines

Recent News About These Companies

Sanofi axes diabetes R&D, focuses on 'transformative' therapies

November 17, 2024 | pharmaphorum.com

Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript

March 21, 2024 | seekingalpha.com

Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript

March 20, 2024 | insidermonkey.com

Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. as President and Vishaal Turakhia as Chief Financial Officer

March 14, 2024 | finance.yahoo.com

Dupixent Redux? Synthekine, Sanofi Partner on Cytokine Therapies

January 29, 2024 | genengnews.com

Sanofi pays Synthekine $40M to join preclinical push against vexing inflammatory target

January 29, 2024 | fiercebiotech.com

Endeavor BioMedicines Appoints Enoch Kariuki, Pharm.D. to Board of Directors

December 19, 2023 | finance.yahoo.com

‘We Have a Whole Ecosystem’: Barbara Borden Reflects on Blockbuster Horizon-Amgen Deal and Life Sciences Deals to Come

November 2, 2023 | law.com

Pegenzileukin by Sanofi for Non-Small Cell Lung Cancer: Likelihood of Approval

October 27, 2023 | pharmaceutical-technology.com

Pegenzileukin by Sanofi for Squamous Cell Carcinoma: Likelihood of Approval

June 10, 2023 | pharmaceutical-technology.com

Pegenzileukin by Sanofi for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

June 10, 2023 | pharmaceutical-technology.com

Merck's $11B Prometheus Acquisition Brings IBD Drug & Precision ... - MedCity News

April 17, 2023 | news.google.com

Capstan Therapeutics Appoints Justin Thacker as Chief Financial ... - Business Wire

March 22, 2023 | news.google.com

Capstan Therapeutics Appoints Justin Thacker as Chief Financial Officer and Jeffrey Pepe, J.D., Ph.D., as General Counsel - Yahoo Finance

March 22, 2023 | news.google.com

Sanofi Goes All In For Type 1 Diabetes With Provention Buy - Scrip

March 13, 2023 | news.google.com

Pegenzileukin by Sanofi for Head And Neck Cancer Squamous Cell Carcinoma: Likelihood of Approval

March 3, 2023 | pharmaceutical-technology.com

Bridge holds firm despite placebo beating drug in midphase ... - FierceBiotech

February 21, 2023 | news.google.com

February 16, 2023 | uk.finance.yahoo.com

Reed Reaches End Of The Road As Sanofi R&D Chief - Scrip

February 13, 2023 | news.google.com

'Robust Ecosystem' Gives Strength to San Diego's Life Science Sector - San Diego Business Journal

February 6, 2023 | news.google.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Chip Giant ASML Gets New Price Targets With Big Upside
By Leo Miller | April 24, 2025
View Chip Giant ASML Gets New Price Targets With Big Upside
Alphabet Rebounds After Strong Earnings and Buyback Announcement
By Ryan Hasson | April 28, 2025
View Alphabet Rebounds After Strong Earnings and Buyback Announcement
Visa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan
By Jeffrey Neal Johnson | May 3, 2025
View Visa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan
3 Stocks Just Announced Intentions to Buyback Near 10% of Shares
By Leo Miller | April 28, 2025
View 3 Stocks Just Announced Intentions to Buyback Near 10% of Shares

THOR, GMED, MASI, and TFX Company Descriptions

Globus Medical NYSE:GMED

$59.00 +0.40 (+0.68%)

Closing price 05/23/2025 03:59 PM Eastern

Extended Trading

$57.97 -1.03 (-1.74%)

As of 05/23/2025 07:44 PM Eastern

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Masimo NASDAQ:MASI

$150.13 +0.22 (+0.15%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$148.48 -1.66 (-1.10%)

As of 05/23/2025 05:27 PM Eastern

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.

Teleflex NYSE:TFX

$120.95 +0.01 (+0.01%)

Closing price 05/23/2025 03:59 PM Eastern

Extended Trading

$124.00 +3.05 (+2.52%)

As of 05/23/2025 08:00 PM Eastern

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Synthorx NASDAQ:THOR

Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time